Shots:

• Novartis will conduct P-I clinical study and will be responsible for the development and regulatory submissions while DNDi will lead P- II & III clinical development with the expected initiation of P-II study in H1’21 in India and additional trials planned in East Africa
• The collaboration b/w the companies is supported with the broader program with the Wellcome Trust and other partners to develop new therapies for visceral leishmaniasis and cutaneous leishmaniasis
• The broader program brings together a strong consortium of R&D partners- including the University of Dundee- GSK- Pfizer- TB Alliance & Takeda. LXE408 is a first-in-class oral therapy- discovered at Novartis with financial support from the Wellcome Trust

Click here to­ read full press release/ article | Ref: Novartis | Image: PMLive